VISIONARY PHARMACEUTICALS, INC.
Biotech · Private
Chiral small-molecule SGK1 inhibitor compounds for thyroid cancer treatment
visionarypharmaceuticals.com →- Grants
- $1.8M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2 | $667,910 | |
| Federal grant | Department of Health and Human Services · Phase I · Identification of RORg drug candidates for the treatment of NASH | $299,985 | |
| Federal grant | Department of Health and Human Services · Phase I · Identification of RORg drug candidates for the treatment of NASH | $156,503 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of dual inhibitors of the kinases SGK1 and AKT1 for blockade of a critical pathway in triple-negative breast cancer | $299,982 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | $86,262 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2166 | PRIME LABS INC | — | — |
| 2167 | Immunovant | — | $450M |
| 2168 | Ocugen | — | $126M |
| 2169 | VISIONARY PHARMACEUTICALS, INC. | — | — |
| 2170 | Excision BioTherapeutics Inc. | — | $71M |
| 2171 | Context Therapeutics | — | $100M |
| 2172 | QT Holdings Corp. | — | $3.8M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.